Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Chronic pain management

Novel drug for chronic migraine approved in Scotland

The first monoclonal antibody therapy for the prevention of chronic migraine has been approved for use by the Scottish Medicines Consortium.

Erenumab (Aimovig; Novartis) will be available through NHS Scotland for people living with chronic migraine, defined as a migraine that occurs on more than 15 days per month, for whom at least three prior treatments have failed.

Erenumab works by targeting the process by which proteins cause blood vessels in the brain to swell, leading to the symptoms associated with migraines. In clinical trials of the drug, patients with chronic migraine experienced an average reduction of 2.5 migraine days per month compared with placebo.

Commenting on the approval, Alok Tyagi, consultant neurologist at the Queen Elizabeth University Hospital in Glasgow, said: “Aimovig has been shown to reduce the average number of monthly migraine days in both episodic and chronic migraine patients, including those who have tried and not had success with existing treatment options.

“Today’s announcement represents a significant milestone for people living with this debilitating condition and marks a new era of migraine management in Scotland.”

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended granting a marketing authorisation for erenumab in June 2018.

In draft guidance published in January 2019, the National Institute for Health and Care Excellence (NICE) rejected erenumab on the basis that the cost-effectiveness estimates for the drug were higher than what is usually considered acceptable in the case of substantial uncertainty. 

However, following a high volume of comments received by NICE on its draft guidance, the appraisal of erenumab for preventing migraine is ongoing, with final guidance expected to be published in summer 2019. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206402

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Physicochemical Principles of Pharmacy

    Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00Buy now
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Introduction to Statistics in Pharmaceutical Clinical Trials

    Introduction to Statistics in Pharmaceutical Clinical Trials

    An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.